GRC 6211

Drug Profile

GRC 6211

Alternative Names: GRC-6211

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Analgesics
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Pain; Urinary incontinence
  • Discontinued Dental pain; Neuropathic pain; Osteoarthritis

Most Recent Events

  • 11 Feb 2011 Phase-I development is ongoing in Urinary incontinence
  • 24 Oct 2008 Suspended - Phase-I for Osteoarthritis in Europe (PO)
  • 07 Nov 2007 Pharmacodynamics data from preclinical studies in rat models of acute and chronic cystitis presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top